Skip to content

CompanyNewsHQ

CompanyNewsHQ

Industry
Companies A-Z
Submit A Press Release
Subscribe
Advertising
Market Analysis
Contact Us

Pharmaceutical Company News

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

November 23, 2020 Michael Crowe AstraZeneca

More from: AstraZeneca | Category: Pharmaceutical Company News

← Non-Jury Trials Justice and Security (Northern Ireland) Act 2007

You May Also Like

AbbVie Declares Quarterly Dividend

February 20, 2020 Michael Crowe

Zoetis to Host Webcast and Conference Call on Second Quarter 2020 Financial Results | Press Releases

June 26, 2020 Michael Crowe

Regeneron Collaborations on Dupixent® (dupilumab) Highlighted During Sanofi R&D Investor Event | Regeneron Pharmaceuticals Inc.

June 11, 2020 Michael Crowe

More Pharmaceutical Company News

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization | Regeneron Pharmaceuticals Inc.
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
Imfinzi approved in the US for less-frequent, fixed-dose use
Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
Predictive analytics could bring medicines to patients faster | Novartis
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age | GSK
Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine
Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine
AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020
Nov 19,2020 | Chugai Receives the Best IR Award | News | CHUGAI PHARMACEUTICAL CO., LTD.
Achieving 100% renewable electricity | Novartis
Novartis set to achieve 100% renewable electricity in its European operations
Novartis set to achieve 100% renewable electricity in its European operations
STERIS Completes Acquisition of Key Surgical | STERIS plc
Pfizer Update On Our U.S. COVID-19 Vaccine Candidate Distribution Preparedness
AbbVie Announces Expiration and Final Results of Registered Exchange Offers
European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
Making Possible: Stepping toward a future with cell and gene therapy | Novartis
Making Possible: Stepping toward a future with cell and gene therapy | Novartis
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

About

Company News HQ is a global business news portal. It is the leading industry news source for major companies across a number of industry verticals.

Links

Advertising
News Tracking Service
Submit News
Subscribe
Contact Us

Copyright © 2020 CompanyNewsHQ. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Industry
▼
Companies A-Z
Submit A Press Release
Subscribe
Advertising
Market Analysis
Contact Us